Cure My Disease

Don't miss your cure!

 Log in / Sign up

CBD shows promise for schizophrenia in new trial

NCT ID NCT02926859

Ongoing Disease control Sponsor: Central Institute of Mental Health, Mannheim Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests whether cannabidiol (CBD) capsules, added to standard antipsychotic medication, can help people with early schizophrenia recover better and stay on treatment longer. 180 participants receive either CBD or placebo for 26 weeks. The goal is to see if CBD improves symptoms and reduces side effects like weight gain and movement problems.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
cannabidiol (CBD) capsules
What this could lead to
If successful, this could point toward a safer, better-tolerated add-on treatment for schizophrenia that helps patients stay on therapy longer.
What could go wrong
This is a mid-stage trial with 180 participants, so results may not apply to all patients. CBD may not outperform placebo, and long-term safety is still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Locations

  • Dep. of Psychiatry and Psychotherapy, Central Institute of Mental Health

    Mannheim, Baden-Wurttemberg, 68159, Germany

  • Department of Psychiatry und Psychotherapy, University Hospital Hamburg-Eppendorf

    Hamburg, 20246, Germany

  • Department of Psychiatry, Psychotherapy, and Psychosomatics, RWTH Aachen

    Aachen, North Rhine-Westphalia, 52074, Germany

  • Dept. of Psychiatry and Psychotherapy, Charité, Campus Charité-Mitte

    Berlin, B, 10117, Germany

  • Dept. of Psychiatry and Psychotherapy, Ludwig-Maximillians-University Munich

    Munich, Bavaria, 80336, Germany

  • Dept. of Psychiatry and Psychotherapy, University Hospital of Cologne

    Cologne, North Rhine-Westphalia, 50924, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.